Team siliconindia

• Launches VITALYFE, an AI-driven platform for cardiometabolic wellness.
• Aims to help working professionals manage early heart health risks.
• To be offered through insurers, brokers, and employers across India.

Lupin Digital Health has launched VITALYFE, an AI-based cardiometabolic wellness platform designed to help Indian working professionals detect and manage early signs of heart health risks. Building on LYFE, Lupin’s CDSCO-approved cardiac care software, VITALYFE extends its technology into preventive and lifestyle wellness.

The platform combines artificial intelligence, behavioural science, and computer-vision technology to identify early cardiometabolic risks and provide personalised lifestyle interventions. It will be made available through insurers, brokers, and employers, integrating seamlessly into existing corporate wellness programmes.

Highlighting the growing concern around heart health, Lupin cited studies showing that up to 80% of India’s corporate workforce display early symptoms of hypertension and dyslipidemia, driven by stress, long working hours, poor diet, and sedentary lifestyles.

Rajeev Sibal, President of India Region Formulations, Lupin, said, “Cardiometabolic risks silently erode both health and productivity”. He added, “With VITALYFE, we are combining clinical expertise with AI technology to deliver measurable wellness outcomes for millions of professionals”.

Also Read: Indian-Made Supraflex Cruz Heart Stent Achieves Global Acclaim

Sidharth Srinivasan, CEO of Lupin Digital Health, added that the platform helps users track their heart age, improve habits, and make informed lifestyle choices. Key features include Heart Age Journey, Snap & Track (photo-based nutrition logging), camera-guided fitness feedback, meditation tools, and gamified wellness challenges.

Compliant with the Digital Personal Data Protection Act and ISO 27001-certified, VITALYFE stores all user data securely within India. It focuses on preventive wellness and is not intended for diagnosis or treatment.